CClinicalTrials.gg
Enrolling by invitationNCT07714161Updated Oct 1, 2026

The Mayo Clinic Rare and Undiagnosed Disease Hackathon

An observational study in Undiagnosed Diseases, Genetic Diseases and Rare Diseases, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Mayo Clinic · Observational

Updated Oct 1, 2026Now Enrolling by invitationStart date movedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Sex
All
01

Study summary

The purpose of this study is to create a Mayo Clinic biospecimen and data repository to support the evaluation of patients with rare and undiagnosed diseases through a structured, multidisciplinary diagnostic program.

02

Conditions studied

  • Undiagnosed Diseases
  • Genetic Diseases
  • Rare Diseases
03

In context

Genetic Diseases, Inborn

403 studies on the registry are indexed under Genetic Diseases, Inborn; 145 are open to participants now.

This study's planned enrollment of 50 is below the median of 192 across 195 observational studies indexed under Genetic Diseases, Inborn.

Browse Genetic Diseases, Inborn studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving or having received care at Mayo Clinic who have rare or undiagnosed conditions and who are nominated by a Mayo Clinic clinician sponsor and selected by the study team.

Inclusion criteria

  • Patients receiving or having received care at Mayo Clinic with rare or undiagnosed conditions; of any age (including pediatric); who can provide informed consent or have a legally authorized representative (LAR).
  • Patients who have undergone prior standard genetic testing that was non-diagnostic; and who are nominated by a Mayo Clinic clinician sponsor and selected by the Study Team.

Exclusion criteria

Exclusion Criteria:

  • Patients with a confirmed molecular or clinical diagnosis that fully explains their phenotype
  • Patients unable to provide consent and without a legally authorized representative (LAR)
  • Patients for whom sample collection cannot be coordinated
  • Patients enrolled in a clinical trial that precludes ancillary genomic research (evaluated on a case-by-case basis)
  • Prisoners will not be included in this study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Rare or Undiagnosed Disease Participants

    Mayo Clinic patients receiving or having received care who have rare or undiagnosed conditions, prior non-diagnostic standard genetic testing, and nomination by a Mayo Clinic clinician sponsor followed by study team selection.

06

What researchers measure

Primary outcomes

  1. Feasibility of establishing a biospecimen and data repository

    Number of enrolled participants who complete all planned repository workflow steps, including eligibility confirmation, informed consent, biospecimen collection, clinical data abstraction, research data generation, and multidisciplinary Hackathon case review.

    Time frame: 1 year

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Enrolling by invitation
changed Oct 1, 2026
Start date
Aug 2026→Jul 24, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Aug 2026→Jul 24, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07714161
Lead sponsor
Mayo Clinic
Responsible party
Eric Klee (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jul 20, 2026
Start date
Jul 24, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 1, 2026

Study contacts

Eric Klee, Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion